63 [6] , and as with FMF, is frequently related to low-penetrance mutations [6] [7] [8] . Patients with adult-onset TRAPS may be characterized by a phenotype that can mimic FMF in the duration of inflammatory attacks, which may last ! 1 week [9] . In addition, patients with adult-onset TRAPS may present with atypical clinical manifestations, such as recurrent serosal involvement of pericardium as the sole clinical manifestation [6] [7] [8] . Among these subjects, we recently hypothesized the criteria (positive family history and poor response to colchicine) for identifying patients for whom testing for genetic mutations of the TNFRSF1A gene should be carried out [7, 8] . In addition, with the aim of improving the genetic diagnosis in adults with suspected autoinflammatory disorders, we have recently identified some variables that appear to be strongly related to the probability of detecting gene mutations in MEFV and TNFRSF1A and we have also developed a diagnostic score for identifying patients at high risk of carrying these mutations (unpublished data, paper submitted). Our score, since the thoracic involvement (pleural and/or pericardial) was included, in addition to the clinical criteria that we previously suggested [7, 8] , might also represent an evidence-based guideline, thus assisting in the diagnostic evaluation of patients with recurrent fever and isolated serosal involvement, and could help identify the few patients among them who may prove to be carriers of mutations in 'autoinflammatory genes'.
In conclusion, we strongly believe that adults presenting with idiopathic recurrent serositis should be evaluated for mutations in the genes responsible for FMF and TRAPS in order to identify patients with FMF and TRAPS, since through lack of an appropriate treatment, they may be at high risk of developing secondary renal amyloidosis. However, genetic testing of all patients presenting with a recurrent inflammatory serosal involvement might have low efficiency and elevated costs. Therefore, more research is needed in order to identify evidence-based criteria for selecting the patients who need to be genetically analyzed for mutations in the autoinflammatory genes.
We read with great interest the article by Lega et al. [1] , who described a patient with familial Mediterranean fever (FMF) who had febrile episodes of right-sided pleuritis, in absence of any extrathoracic complaints. The patient did not fulfill the diagnostic criteria for FMF [2] , nevertheless colchicine administration led to the complete resolution of attacks, and genetic testing further strengthened the presumptive diagnosis, since the patient showed a homozygous M694I/M694I mutation in the MEFV gene. The article by Lega et al. suggests that autoinflammatory disorders, mainly when the onset is in adulthood, may sometimes present with isolated serosal involvement. Since an increasing interest is currently being devoted to serositis and autoinflammatory disorders [3] , we would like to present some additional data on our personal experience with adult-onset autoinflammatory disorders and their presentation with isolated serosal involvement occurring with fever.
To date, among monogenic periodic fever syndromes, a late onset of symptoms is reported both for FMF [4] , up to the age of 65 [5] , and for tumor necrosis factor receptor-associated periodic syndrome (TRAPS) [6] [7] [8] . FMF, caused by mutations in the MEFV gene, and TRAPS, caused by mutations in the TNFRSF1A gene, are respectively the most common autoinflammatory recessive and autosomal dominant disorders and are characterized by recurrent episodes of fever associated with abdominal and chest pain, arthralgia and/or arthritis, and cutaneous manifestations. Adult-onset FMF is usually related to low-penetrance mutations, and patients may experience milder disease, although the clinical manifestations are usually similar to those of younger patients, with the exception of arthritis and erysipelas-like erythema, which are significantly less frequent in adults [3] . Disease onset in adulthood has been described for TRAPS as well, up to the age of
